Index

Acquired delayed ejaculation, 237-238 methodology, 238 organic factors, 237 psychological factors, 237 research, 238 treatment, 237-238 Aging, effect on, ejaculation, 230 Albumin, testosterone, 83 Androgen decline in the aging male

(ADAM), 98 Androgen deficiency syndrome, criteria, 52 Androgens, 50

Andropause (ADAM, PADAM) diagnosis, 98

hypogonadal syndrome, 97 -99 Anesthetic ejaculation, 239 definition, 239 etiology, 240 symptoms, 239 treatment, 240 Anesthetic topical ointments, premature ejaculation, 232

Anhedonia, ejaculatory, 239 Antidepressant drugs causing

ED, 158 Antidepressants, premature ejaculation, 232

Anxiety reduction technique, for ED, 205-206 Apomorphine, pharmacotherapy,

ED, 176-177 Arousability, low sexual desire, 48-50 Assessment, biopsychosocial, sexual, 58 Assessment, male sexual dysfunction, 80-83

Biopsychosocial treatment, female sexual desire, 56-57 Biopsychosocial, sexual assessment, 58

Cialis, tadalafil, 174-174 Classification systems

Consensus Classification, 115 DSM-IV-TR, 115 Clinicians, sex counseling by, 24-34 focused sex history, 25-27 partner issues, 30-32 patient preference, 27-29 pharmaceutical choice, 27-29 relapse prevention, 30-32 sexual scripts, 27-29 therapeutic probe, 27-29 weaning, 30-32 Clitoris, in FSAD, 127-128

Cognitive-behavorial approaches, female orgasm disorder, treatment of, 203-207 Combination therapy (CT), 21 guidelines, 22-24 sexual dysfunction and, 15-38 history of, 21-22 Comorbidity, paraphilias,

297-298 Constriction rings, as treatment for ED, 180-181 Courtship disorder (paraphilias), etiology, 311 CSA (child sexual abuse), 91

Dehydroepiandrosterone (DHEA), 51, 87

Dehydroepiandrosterone sulfate

(DHEAS), 51, 87 Dehydrotestosterone (DHT), 51 Delayed ejaculation, lifelong, 235-237 neurobiological approach,

235-237 psychological approach, 235 treatment of, 236-237 retarded ejaculation, 235-237 Depression, serotonin reuptake inhibitors, 184 Diagnostic systems, sexual, 6-7 Dihydrotestosterone (DHT), 86 Directed masturbation (DM),

203-205 DM (directed masturbation),

203-205 Drug treatment, for premature ejaculation, 224-227 Drug-induced diminished desire, testosterone in, 104 Drugs effects, on female orgasm,

198-201 DSM-IV-TR, revision for sexual aversion, 115 Dyspareunia, 249 -267 assessment of, 253-254 classification of, 252-253 definition, 250-251 diagnosis of, 253-254

postmenopausal, 256-257 treatment of, 251-252 vulvar vestibulitis syndrome, 254-255 vulvodynia, 255-256

ED (erectile dysfunction), 17, 155-185 anatomy and physiology, 159-161 antidepressant drugs causing, 158 basic causes, 156-159 etiological factors, 161 -163 history and clinical examination, 163-166

hyperprolactinaemia, causes of, 163 medical treatment, 17 sildenafil, 17 tadalafil, 17 vardenafil, 17 pathophysiology, 161 pharmacotherapy apomorphine, 176-177 centrally acting oral treatment,

176-178 phosphodieterase 5, 167-176 yohimbine, 177-178 treatment, 166

constriction rings, 180-181 injectable and intraurethral, 178 -180 integrated therapies, 182-183 pharmacotherapy, 166-181 for priapism, 183 psychological therapies, 181 psychosexual, 182 relationship therapy, 182 surgical intervention, 183-184 unlicensed therapies, 183 vacuum constriction devices, 180-181 Ejaculation disorders

5-HT receptors, 219-220 acquired delayed, 237-238 aging, effect on, 230 anesthetic, 239-240 brain imaging studies, 222-223 neuroanatomy, 221-222 neurobiology, 219 -223 neurophysiology, 218-219 orgasm, male, differences between, 217-218

painful, 241 premature, 223-233

drug treatment, 231-233 ejaculation distribution theory,

227-229 evidence-based medicine, 224-227 genetics, 230-231 history, 223 -224 operational definition, 227 prevalence, 224 treatment, 231-233 retarded, 233-238 definition of, 234 lifelong delayed, 235 prevalence, 234-235 symptoms, 234 retrograde, 238-239 definition, 238 etiology, 239 symptoms, 238-239 treatment, 239

serotonin, 219-220 Ejaculation distribution theory,

227-229 Ejaculation threshold hypothesis, 229 Ejaculatory anhedonia, 239 Ejaculatory incompetence, partial, 240 Endocrine abnormalities, HSDD, 89 Erection, anatomy and physiology, 159-161

Etiological factors, of ED, 161-163 Etiology, of HSDD, 88-97 Eugonadal, 86

Exhibitionism, paraphilias, 298

Female hypoactive desire disorder, 43 -59 arousability, 48 assessment of, 48-50 biology of, 50 -53 biopsychosocial treatment, 56-57 blended sex response cycle model, 47 DSM-IV definition, 48-49 hormonal treatment, 55 -56 management of, 53 -57

markers of desire, 48 pharmacological treatment

(nonhormonal), 55 psychological treatments, 53 -55 reasons for, 45-46 recommendations for, 5759 response models, 46-48 sex response cycle model, 47 Female orgasm disorder (FOD), 127, 193-209 clinical definition of, 202-203 orgasm, treatment of, 203 -207 treatment of, cognitive-behavioral approaches, 203 -207 treatment of, pharmacological approaches, 203 -207 Female sexual desire biological basis, 50-53 biopsychosocial treatment, 56-57

management of low desire/interest, 53-57

pharmacological treatment,

55-56 psychological treatment, 53-55

recommendations for, 57, 59 Female sexual dysfunction, 1999

consensus classification, 114 Female sexual feelings, 138-140 Female sexual function index

(FSFI), 136 Female sexual response, activation and regulation of, 136-143 Female, orgasm, 197-198 disorder clinical definition of, 202-203 cognitive-behavorial treatment,

203 -207 pharmacological treatment,

203 -207 treatment of, 203-207 drugs, effects on, 198 -201 psychosocial effects on, 201-202 Female, sex initiation by, reasons 45-46 Female sexual dysfunction, defined, 141-143

Female sexual response, 136-143 Fetishism, paraphilias, 302-303 Frotteurism, 300

FSAD (female sexual arousal disorder), 123-147 anatomy and physiology, 127-129 current status of knowledge, 127-136 diagnosing of, 129-131 diagnostic procedures, 134-136 female sexual response, 136-143 genital responsiveness, 132-134 prevalence of, 127 studies, history, of, 124-127 treatment, 143-147 pharmacotherapy, 144-147 psychological, 143-144

Genetics in premature ejaculation, 230-231 in vulvar vestibulitis syndrome, 260

5-Hydroxytryptamine neurotransmission (5-HT) receptors ejaculation, 219 -220 male rat sexual behavior, 220 Hematopoiesis, TRT and, 103-104 Hormonal treatment male sexual dysfunction, 83-87 testosterone, 55-56, 83-87 tibolene, 56

vulvar vestibulitis syndrome, 259 HSDD (hypoactive sexual desire disorder) female, 43-59 arousability, 48 assessment of, 48-50 biology of, 50-53 biopsychosocial treatment, 56-57

blended sex response cycle model, 47 DSM-IV definition, 48-49 hormonal treatment, 55-56 management of, 53 -57 markers of desire, 48 pharmacological treatment

(nonhormonal), 55 psychological treatments, 53-55

reasons for, 45-46 recommendations for, 57, 59 response models, 46-48 sex response cycle model, 47 male, 69-106

acquired and generalized, 77-78 child sexual abuse (CSA), 91 drug treatment, 93-96, 101 endocrine abnormalities, 89 etiology, 88-97 hypogonadal syndrome, age related, 97-99 ill partner, 96 lifelong and situational disinterest, 76-77 Madonna/prostitute syndrome, 96 medical disorders, 91 other sexual/gender disorders in patient, 89-90 psychiatric disorders, 93 psychotherapy, 100-101 relationship discord, 97 sexual difficulties with partner,

90-91 subtypes, 74-78 testosterone, 102-104 treatment, 99-104 Hyperprolactinaemia causes of, 163 TRT and, 104 Hypoactive desire disorder, female. See Female hypoactive desire disorder. Hypoactive sexual desire disorder, male. See Male hypoactive desire disorder. Hypogonadal syndrome age related, 97-99

andropause (ADAM, PADAM), 97-99 etiology, 99 Hypogonadism, 97-98 Hypothalamic prolactin-inhibiting hormone (PIH), 87

Inhibited sexual desire (ISD), 78 International Association for the Study of Pain (IASP), 253

International Inventory of Erectile

Function (IIEF), 164 Intravaginal ejaculation latency time (IELT), 228

Latent class analysis (LCA), 79 Levitra, vardenafil, 174-175 Lifelong delayed ejaculation, 235-237 neurobiological approach, 235-237 psychological approach, 235 treatment of, 236-237 retarded ejaculation, 235-237

Madonna/prostitute syndrome, in HSDD, 96 Male ejaculation disorders, 215-242

Male hypoactive sexual desire disorder (HSDD), 67-106 acquired and generalized, 77-78 child sexual abuse (CSA), 91 drug treatment, 93 -96, 101 endocrine abnormalities, 89 etiology, 88-97

hypogonadal syndrome, age related,

97-99 ill partner, 96

lifelong and situational disinterest,

76-77 Madonna/prostitute syndrome, 96 medical disorders, 91 other sexual/gender disorders in patient, 89-90 psychiatric disorders, 93 psychotherapy, 100-101 relationship discord, 97 sexual difficulties with partner,

90-91 subtypes, 74-78 testosterone, 102-104 treatment, 99-104 Male Impotence Diagnostic Ultrasound System (MIDUS), 165 Male orgasm, neurophysiology, 219 Male orgasmic disorders, 215 -242

Male sexual desire disorder, assessment of, 75 Male sexual dysfunction assessment, 80-83 history, 80-82 hormones, 83 -87 laboratory examination, 83 pattern determination, 81 physical examination, 82 Massachusetts Male Aging Study

(MMAS), 72 Masters and Johnson, 15-17 Medical diagnostic criteria, sexual aversion, 113-120 Medical disorders, and HSDD, 91 Medical treatments, for ED, 17 Medicated urethral system for erection

(MUSE), 179 Medication of, sexuality, 8 Men, sexual disinterest, epidemiology, 78 MIDUS, male impotence diagnostic ultrasound system, 165 Monamine oxidase inhibitors (MAOIs), in sexual aversion disorders, 119

National Health and Social Life Survey (NHSLS), 78-80 Neuroanatomy, ejaculation, 221-222 Neurobiology, of ejaculation,

219-223 Neurophysiology, of ejaculation, 218-219

Neurophysiology, of male orgasm, 219 Nocturnal electronic volumetric assessment (NEVA), 165 Nocturnal penile tumescence

(NPT), 165 Nomenclature, of sexual dysfunction, 5-6

Organic/psychogenic factors, sexual dysfunction, 14-15 Orgasm causes of, 196 definition of, 194-196 female, reasons for, 197-198 drugs effects on, 198 -201

Orgasm (Contd.)

psychosocial effects on, 201-202 female orgasm disorder clinical definition of, 202-203 cognitive-behavorial treatment,

203-207 pharmacological treatment,

203-207 treatment of, 203 -207 gender differences in, 196-197 male ejaculation differences between, 217 -218 neurophysiology, 219

PADAM (partial ADAM), 98 and ADAM, 97-99 diagnosis of, 98 Paraphilias, 293-323 comorbidity, 297-298 conceptualizing of, 294-295 definition of, 294-295 DMS-IV-TR criteria summary, 299 etiology of, 307-314

behavioral models, 309-311 biological theories, 312-314 courtship disorder theory, 311 family dysfunction models, 309 personality theories, 311-312 psychoanalytic models, 307-308 exhibitionism, 298 fetishism, 302-303 frotteurism, 300 gender, 296-297 other types, 306-7 pedophilia, 305-306 prevalence, 295-296 sexual sadism/masochism, 300-302 transvestic, 303-305 treatment, 314-322

pharmacological, 314-317 psychological, 317-322 voyeurism, 298 Partial ejaculatory incompetence, 240 etiology, 240 treatment, 241 Partner issues, 30-32 Pathophysiology, of ED, 161

PDE5 (phosphodieterase-5), for ED,

167-176 PDE5 inhibitors phosphodieterase-5, 167-176 sildenafil (Viagra), 167-173 tadalafil, 173-174 vardenafil, 174-175 Viagra 167-173 PDE5 treatments, 17 Pedophilia, paraphilias, 305-306 Personality theories, paraphilias, etiology, 311-312 Pharmaceutical choices, 27-29 Pharmacological approaches, female orgasm disorder, 203 -207 Pharmacological treatment, female sexual desire, 55-56 hormonal, 55-56 nonhormonal, 55 Pharmacological, paraphilias, treatment of, 314-317 Pharmacology, for sexual aversion disorder, 119-120 Pharmacotherapy FSAD, 144-147 sexual dysfunction, 13 -41 Pharmacotherapeutic agents, 166-181 apomorphine, 176-177 centrally acting oral treatment,

176-178 phosphodieterase-5, 167-176 yohimbine, 177-178 Phosphodieterase-5. See PDE5. PIH (hypothalamic prolactin-inhibiting hormone), 87 Positron emission tomography

(PET), 222 Postmenopausal dyspareunia, 256-257 vulvar postmenopausal dyspareunia, 266 vulvar vestibulitis syndrome, 262 Postorgasmic illness syndrome, 241 -242 Premature ejaculation, 223-230 aging, effect on, 230 definition, 227 drug treatment, 231-233

anesthetic topical ointments, 232 antidepressants, 232

serotonergic antidepressants, 232 ejaculation distribution, theory, 227-229

ejaculation threshold hypothesis, 229 evidence-based medicine, 224-227 drug treatment, 224-227 psychotherapy, 224-227 genetics, 230-231 history, 223-224 prevalence, 224 treatment, 231-233 behavorial therapy, 233 psychotherapy, 233 Priapism, as treatment for ED, 183 Prolactin (PRL), 83, 87-88 Prostate-specific antigen (PSA), 103 Prostheses, as treatment for ED, 183-184

Psychiatric disorders, HSDD and, 93 Psychogenic factors, sexual dysfunction, 14-15 Psychological therapies ED, 181-182

female sexual desire, 53 -55 FSAD, 143-144 paraphilias, 317-322 Psychosocial barriers, sexual pharmaceuticals, 19-20 Psychosocial effects, on female orgasm, 201-202 Psychosocial obstacles (PSO), 22 Psychotherapy for HSDD, 100-101 for premature, ejaculation, 224-227, 233 Putative prolactin-releasing hormone (PRH), 87

RE. See Retarded ejaculation. Referrals, patient, 33 -34 Relapse prevention, 30-32 Relationship discord, in HSDD, 97 Relationship therapy, as treatment for

ED, 182 Retarded ejaculation (RE), 21, 233-238 definition of, 234 lifelong, 235

prevalence, 234-235 symptoms, 234 Retrograde ejaculation, 238-239 definition, 238 etiology, 239 symptoms, 238-239 treatment, 239 Rings, constriction, as treatment for ED, 180-181

Sadomasochism, 300-302 SD treatment, multidisciplinary team approach, 35-38 Selective serotonin reuptake inhibitors

(SSRIs), 119, 198-201, 220 Serotonergic antidepressants, in premature ejaculation, 232 Serotonin, role in ejaculation,

219-220 Serotonin reuptake inhibitors, for depression, 184 Sex counseling partner issues, 30-32 patient preference, 27-29 pharmaceutical choice, 27 -29 relapse prevention, 30-32 sexual scripts, 27-29 therapeutic probe, 27-29 weaning, 30-32 Sex initiation, female, reasons for, 45-46

Sex response cycle (SRC), 47, 73

blended, 47 Sex therapy options, 48-50 pharmacotherapy, 13 -41 treatment models, 15-17 Masters and Johnson, 15-17 Sexual activity acceptance, female, reasons for, 45 -46 Sexual arousability, 48 Sexual aversion disorder (SAD), 74, 111-120 classification system

(DSM-IV-TR), 115 cognitive behavioral treatment, 118 diagnostic criteria revision, 115-120

Sexual aversion disorder (SAD) (Contd.) insight-oriented treatment, 118-119

medical diagnostic criteria, 113-115 pharmacology, 119-120 Sexual desire arousability, 48-50 gender differences, 69-72 men, normal, 72-73 Sexual desire disorders (SDD), 74

male, assessment of, 75 Sexual diagnostic systems, 6-7 Sexual difficulties, with partner in HSDD, 90-91 Sexual disinterest, in men, 78 Sexual dysfunction combination therapy, 21-24 epidemiology of, 4-5 evolving models of, 6 -7 female, defined, 141-143 nomenclature of, 5-6 organic/psychogenic factors, 14-15 pharmacotherapy, 13 -41 perspectives on, 7-8 treatment models, 15-17 Sexual feelings, gender differences, 140-141

Sexual issues, medical classification of, 73 -78 Sexual pharmaceuticals failure vs. success factors, 18 psychosocial barriers, 19-20 Sexual sadomasochism, 300-302 Sexual scripts, 27-29 Sexual treatment approaches, history of, 2-4

Sexual trigger mechanisms, 46-47 Sexuality biopsychosocial assessment of, 58 medication of, 8 SHBG (sex hormone blinding globulin), 83 Sildenafil (Viagra), 167-173

as medical treatment for ED, 17 Surgical intervention, for ED prostheses, 183-184 vascular, 183-184

Tadalafil (Cialis), 173-174 for ED, 17 as PDE5, 173-174 Testosterone, 51 actions, 86 albumin, 83

as hormonal treatment, 55-56 changes with age, 84-85, 87 components/measurements, 83 - 84 deficiency, 184 free, 83

HSDD, in treatment of, 102-104 production and regulation, 85-86 sex hormone binding globulin

(SHBG), 83 sexuality, effects on, 86 Therapeutic probe, 27-29 Tibolene, as hormonal treatment, 56 Topical ointments, for premature ejaculation, 232 Transvestic, paraphilias, 303-305 Treatment models

Masters and Johnson, 15-17 for sexual dysfunction, 15 -17 TRT (testosterone replacement therapy), 103 for drug-induced diminished desire, 104 for hematopoiesis, 103-104 for hyperprolactinemia, 104

Vacuum constriction devices (VCD), for ED, 180-181 Vaginal pulse amplitude (VPA), 132

Vaginal wall, in FSAD, 128-129 Vaginismus, 273-289 causes of, 275-280 definition, 274-275 treatment, 280-289 Vardenafil (Levita), for treatment of

ED, 17, 174-175 Vascular, surgical intervention, for

ED, 183-184 Viagra (sildenafil), 167-173 Voyeurism, 298 Vulvar postmenopausal dyspareunia, 266

Vulvar vestibulitis syndrome, 254-255 etiology, 258-261 genetic factors, 260 hormonal factors, 259 psychological factors, 260-261 relationship factors, 260 yeast infections, 259 postmenopausal dyspareunia, 262 treatment of, 263-265

vulvodynia, 261-262, 266 Vulvodynia dyspareunia, 255-256 vulvar vestibulitis syndrome, 261-262 treatment of, 266

Weaning, 30-32

Yeast infections, etiology of, 259 Yohimbine, for ED, 177-178

Natural Remedy For Yeast Infections

Natural Remedy For Yeast Infections

If you have ever had to put up with the misery of having a yeast infection, you will undoubtedly know just how much of a ‘bummer’ it is.

Get My Free Ebook


Post a comment